Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
11.32
-0.11 (-0.96%)
Aug 12, 2025, 4:00 PM - Market closed
Aurinia Pharmaceuticals Employees
Aurinia Pharmaceuticals had 130 employees as of December 31, 2024. The number of employees decreased by 170 or -56.67% compared to the previous year.
Employees
130
Change (1Y)
-170
Growth (1Y)
-56.67%
Revenue / Employee
$2,000,854
Profits / Employee
$466,431
Market Cap
1.49B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 130 | -170 | -56.67% |
| Dec 31, 2023 | 300 | 0 | - |
| Dec 31, 2022 | 300 | 0 | - |
| Dec 31, 2021 | 300 | 6 | 2.04% |
| Dec 31, 2020 | 294 | 232 | 374.19% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AUPH News
- 6 days ago - Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade) - Seeking Alpha
- 12 days ago - Aurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025 - Business Wire
- 22 days ago - Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 - Business Wire
- 5 weeks ago - The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity - Seeking Alpha
- 6 weeks ago - Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) - Business Wire
- 6 weeks ago - Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025 - Business Wire
- 2 months ago - New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis - Business Wire